Skip to Content


In the US, Sipuleucel-T (sipuleucel-T systemic) is a member of the drug class therapeutic vaccines and is used to treat Prostate Cancer.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Therapeutic Category

Antineoplastic vaccine (against prostate cancer)

Chemical Name

Specific active immunotherapeutic composed of antigen-loaded autologous antigen presenting cells designed to stimulate a T cell immune response specific for the tumor-associated antigen prostatic acid phosphatase (PAP) (USAN)

Foreign Names

  • Sipuleucel-T (German)
  • Sipuleucel-T (French)
  • Sipuleucel-T (Spanish)

Generic Names

  • Sipuleucel-T (OS: USAN)
  • APC8015 (IS)
  • Sipuleucel-T (PH: USP 38)

Brand Names

  • Provenge
    Dendreon, United States; Dendreon UK, Poland


ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.